Abstract
e19583 Background: Monitoring the quality of life (QoL) is very important for patients (pts) during breast cancer (BC) treatment (Tx). We aimed to determine the factors affecting QoL among pts with BC in Turkey. Methods: We measured the QoL of pts with BC by using the version of 12-item SF-12 QoL Scale. We also evaluated the clinical validity of Turkish versions of other QoL questionnaires including EORTC, QLQ-C30, Rosenberg, FACT, FLIC, and EQ-5D, as well as the associations among those. Results: A total of 916 out of 1,000 enrolled pts with BC were eligible for the study. The mean age at study entry was 52.2±12.2 years. Education level, comorbidity, disease stage, performance status, time from diagnosis (Dx), metastatic disease, and the Dx/Tx combination were the factors affecting QoL. The lowest QoL score was in metastatic pts who were treated with chemotherapy. Age, income, and local recurrence did not effect QoL in these pts. SF-12 correlated moderately with FLIC, EORTC and EQ-5D (r=-.54, .50 and .41; all p<0.001). The highest internal consistency was obtained with the EORTC scale (Cronbach’s α= 0.88). Conclusions: QoL scales showed low to moderate correlations with each other. They evaluate different aspects of the QoL in BC pts and, except for Rosenberg, are sensitive to clinical variations. SF-12 p EORTC p FACT p FLIC p EQ5D p Rosenberg p Stage I-II 44 ± 10 .001 67 ± 23 .023 4.6 ± 3.0 .30 88 ± 10 .040 75 ± 19 .10 23.3 ± 3.8 .10 III-IV 40 ± 10 61 ± 24 5.0 ± 3.2 90 ± 10 71 ± 20 22.6 ± 4.0 ECOG PS ≤1 43 ± 9 .001 66 ± 22 .023 4.4 ± 2.9 .002 88 ± 10 .003 75 ± 18 <.001 23.0 ± 3.9 .76 >1 38 ± 11 59 ± 24 5.7 ± 3.2 92 ± 10 66 ± 21 23.1 ± 4.0 Dx/Tx status NED-No T 44 ± 9 <.001 66 ± 23 .004 3.8 ± 2.3 .001 86 ± 7 .003 76 ± 15 .033 22.8 ± 4.3 .87 NED-HT 45 ± 10 68 ± 21 4.5 ± 3.0 88 ± 10 75 ± 18 23.5 ± 3.4 NED-CT 40 ± 10 66 ± 23 5.7 ± 3.3 92 ± 10 72 ± 21 23.1 ± 3.8 Met-HT 39 ± 10 64 ± 25 3.6 ± 2.5 89 ± 11 72 ± 17 22.4 ± 3.9 Met-CT 37 ± 10 52 ± 23 5.2 ± 3.5 91 ± 11 66 ± 21 22.8 ± 4.4 Time post Dx (yrs) ≤1 40 ± 10 <.001 65 ± 24 .11 5.8 ± 3.4 .001 91 ± 10 .003 72 ± 19 .033 23.1 ± 3.9 .87 1-3 44 ± 10 68 ± 24 4.3 ± 3.0 87 ± 10 73 ± 18 23.0 ± 4.0 >3 43 ± 10 61 ± 23 4.1 ± 2.6 88 ± 10 74 ± 18 23.0 ± 3.9
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
